Literature DB >> 23151381

Effect of Australian elapid venoms on blood coagulation: Australian Snakebite Project (ASP-17).

Abhishek Gulati1, Geoffrey K Isbister, Stephen B Duffull.   

Abstract

Snake venoms contain toxins that activate the coagulation network and cause venom-induced consumption coagulopathy. A previously developed mathematical model of the coagulation network was refined and used to describe and predict the time course of changes in the coagulation factors following envenomation by Brown snake (Pseudonaja spp.), Tiger snake (Notechis scutatus), Rough-scaled snake (Tropidechis carinatus) and Hoplocephalus spp. (Stephens banded, Pale headed and Broad headed). Simulations of the time course of the change in coagulation factors were compared to data obtained from a large prospective study of Australian snake bites - the Australian Snakebite Project. The model predictions were also compared against data for partial and complete VICC obtained from the same study. The model simulations were used to understand the differences in consumption and recovery of clotting factors in partial versus complete VICC as well as among bites from different snake types. The model suggested that the venoms were absorbed almost instantaneously and provided a reasonable prediction of the observed concentration of clotting factors over time in patients bitten by Australian elapid snakes. The model predictions suggested a higher consumption of factors (fibrinogen, II and IX in particular) in patients with complete VICC compared to those with partial VICC. The model also predicted that snakes with "Xa-like" venoms may produce a less severe VICC than snakes with "Xa:Va-like" venoms.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23151381     DOI: 10.1016/j.toxicon.2012.11.001

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  10 in total

1.  Application of Adaptive DP-optimality to Design a Pilot Study for a Clotting Time Test for Enoxaparin.

Authors:  Abhishek Gulati; James M Faed; Geoffrey K Isbister; Stephen B Duffull
Journal:  Pharm Res       Date:  2015-07-01       Impact factor: 4.200

2.  Understanding and reducing complex systems pharmacology models based on a novel input-response index.

Authors:  Jane Knöchel; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-12-14       Impact factor: 2.745

3.  The clinical utility of pharmacometric models.

Authors:  Shaun S Kumar; Eman Biltaji; Robert Bies; Catherine M Sherwin
Journal:  Br J Clin Pharmacol       Date:  2018-05-02       Impact factor: 4.335

Review 4.  Managing snakebite.

Authors:  Ravikar Ralph; Mohammad Abul Faiz; Sanjib Kumar Sharma; Isabela Ribeiro; François Chappuis
Journal:  BMJ       Date:  2022-01-07

5.  Using a Systems Pharmacology Model of the Blood Coagulation Network to Predict the Effects of Various Therapies on Biomarkers.

Authors:  S Nayak; D Lee; S Patel-Hett; D D Pittman; S W Martin; A C Heatherington; P Vicini; F Hua
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-19

6.  Scale reduction of a systems coagulation model with an application to modeling pharmacokinetic-pharmacodynamic data.

Authors:  A Gulati; G K Isbister; S B Duffull
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-01-08

7.  Current treatment for venom-induced consumption coagulopathy resulting from snakebite.

Authors:  Kalana Maduwage; Geoffrey K Isbister
Journal:  PLoS Negl Trop Dis       Date:  2014-10-23

Review 8.  A Philosophical Framework for Integrating Systems Pharmacology Models Into Pharmacometrics.

Authors:  S B Duffull
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-11-12

9.  D-dimer testing for early detection of venom-induced consumption coagulopathy after snakebite in Australia (ASP-29).

Authors:  Geoffrey K Isbister; Tina Noutsos; Shane Jenkins; Katherine Z Isoardi; Jessamine Soderstrom; Nicholas A Buckley
Journal:  Med J Aust       Date:  2022-06-07       Impact factor: 12.776

10.  Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.

Authors:  Matthew Lewin; Stephen Samuel; Janie Merkel; Philip Bickler
Journal:  Toxins (Basel)       Date:  2016-08-25       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.